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a b s t r a c t
This study aimed to make a picture of patients at highest risk of developing contrast
induced nephropathy (CIN) in order to take appropriate prevention measures. 591 patients
undergoing coronary procedures were divided up into two groups: patients with (CIN-
group) and without (no-CIN) an increase in creatinine level equal or more than 25% from
baseline values within 24e48 h after the coronary procedure. All patients underwent an
accurate anamnesis, objective exam, hematochemical measurements, and diagnostic
exams. The results of this study one hand confirmed that, average age ( p ¼ 0.01), diabetes
mellitus ( p < 0.0001), kidney failure ( p ¼ 0.0001), diuretic therapy ( p ¼ 0.002), higher
contrast doses ( p ¼ 0.01), are associated with a higher risk of contrast-induced nephrop-
athy, on the other suggested that both clinical ( p ¼ 0.01) and subclinical ( p < 0.0001)
atherosclerosis, and higher preprocedural high sensitive C-reactive protein (hs- CRP)
( p ¼ 0.02) may more exposed to CIN.
Copyright ª 2012, Cardiological Society of India. All rights reserved.
1. Introduction
Contrast-induced nephropathy (CIN) is the third leading cause
of hospital-acquired acute renal failure, accounting for 10% of
all cases of hospital-acquired renal failure.1 It is commonly
defined as an acute deterioration of the renal function char-
acterized by a significant increase in creatinine serum levels,
usually more than 0.5 mg/dl (44 mmol/L) or 25% of baseline
levels, within 24e48 h after exposure to a contrast agent
compared to baseline serum creatinine values, when alter-
native explanations for renal impairment have been
excluded.2 The CIN represents an actual problem associated
with increased mortality and morbidity and costs,3e5 in fact,
although usually transient, its resolution needs 1e3 weeks in
average, the impairment of renal function may be permanent
in some cases with the risk of progression towards chronic
renal failure and the necessity of a temporary or lasting dial-
ysis.6 Prevention is the key to reduce the incidence of CIN and
it begins with identification of the high risk patient coupled
with appropriate peri-procedural management. Many studies
have been conducted to identify the main risk factors for CIN,
in fact many score systems have been proposed7e12 and
increasing number of guidelines have been suggested in
literature13,14 to help lessen the complication of CIN.
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A strong correlation was found between risk of CIN and
pre-existing renal impairment, diabetes mellitus, advanced
age, peri-procedural intravascular depletion, congestive heart
failure, volume and type of contrast administered, and
concomitant use of other nephrotoxic drug.5,7,15 Few studies
have, instead, investigated the role of systemic inflammation
and extracardiac atherosclerosis as possible independent
predictors of CIN. Some recent study found that elevated pre-
procedural C-reactive protein (CRP) levels may be associated
with an increased risk for CIN after percutaneous coronary
intervention (PCI).16,17
The aim of this study was to make a picture of patients at
highest risk of developing CIN after coronary angiography
and/or percutaneous coronary intervention, in order to take
appropriate prevention measures, analyzing the risk factor,
evaluated extensively in the literature, and assessing if other
factor, asmarker of inflammation and atherosclerosis, may be
considered independent predictor for CIN.
2. Material and methods
2.1. Study population
In our clinical experience we assessed a population composed
of 1300 consecutive patients undergoing coronary angiog-
raphy and, if necessary, elective or emergency percutaneous
coronary intervention from October 2006 to June 2008 in
Center for the Early Diagnosis of Preclinical and Multifocal
Atherosclerosis and for the Secondary Prevention, University
Hospital “P. Giaccone” of the University of PalermoeItaly. We
excluded the patients admitted in other departments after
procedures, making impossible to monitor their clinical
conditions and to perform hematochemical surveys, in preg-
nancy, underwent coronary artery by pass graft (CABG) within
48 of coronary angioplasty, with many different causes which
had avoided the evaluation of CRP levels and creatinine serum
level at admission, with life expectancy<1 year. Patients were
also excluded if they had concomitant inflammatory condi-
tions (such as active infection, inflammatory arthritis or
connective tissue disease) or malignancies or had recent (<4
months) surgery or major trauma.
In this manner, a final sample size of 591 (45.46%) of 1300
patients were enrolled and underwent an accurate anam-
nesis, objective exam, haematochemical measurements, the
ultrasonography of carotid arteries and ankle-brachial pres-
sure index (ABI) measurements.
The database compiled for each patient contains the data
listed in Table 1.
Family history of CAD (Coronary artery disease) was
defined as a coronary event occurring before 55 and 65 years,
for first-degree male and female, respectively. Diabetes mel-
litus was defined as a fasting glucose #126 mg/dl on at least
two separate occasions or as the use hypoglycemic drugs.18
Hypertension was defined as a blood pressure >140/
90mmHg or as use antihypertensive drugs.Q1 Present smokers if
they were current smokers or had stopped since less than 1
year. Obesity was defined as a body max index #30 kg/m2.
Anemia was defined as hemoglobin level less than 13 g/dl in
men and less than 12 g/dl in women.19 Dyslipidemia defined
as plasma triglycerides >150 mg/dL and/or plasma low-
density lipoprotein cholesterol (LDL-C) >130 mg/dL and or
plasma (high-density lipoprotein-cholesterol) HDL-C <40 mg/
dL in men and <50 mg/dL in women. Multivessel CAD was
defined as two or more lesion (>50%) in different epicardial
coronary arteries.
The presence of extracoronary atherosclerosis we
demonstrated by echo-color Doppler exams and measure-
ment of ABI (Ankle Brachial Pressure) performed before or
during stay in hospital, taking into account any site: carotid
vessels and inferior limbs. In our study we considered the
term of extracoronary atherosclerosis both clinical athero-
sclerosis and preclinical atherosclerosis.
Chronic Renal Insufficiency (CRI), assessed at admission,
was defined as an estimated Glomerular Filtration Rate (eGFR)
below 60 mL/min/1.73 m and calculated using a modified
MDRD equation.
All patients were closely monitored during their stay in
hospital to assess their creatinine serum peak 3e4 days after
contrast procedure: if subjects were discharged earlier, they
were invited to undergo a blood sample privately and to
transmit us their results. Two groups of patients were indi-
vidualized in the study population: age according to
percentage variation of serum creatinine between the pre and
the post procedural phase: “CIN-group” and “no-CIN group”.
CIN was defined as an absolute increase in serum creati-
nine of 25% from baseline values occurring within 24e48 h
after the coronary procedure.2
2.2. Biochemistry
A blood sample was drawn in themorning, before themedical
examination, after a 12e14 h overnight fast Total cholesterol
(TC), triglycerides (TG), and HDL-cholesterol were quantified
by standard enzymatic-colorimetric methods20 and LDL-
cholesterol was calculated by Friedewald’s method.
The patients had blood drawn for hs-CRP analysis
immediately before primary coronary intervention.
High sensitive (hs)-CRP was determined by the nephelo-
metric method (Beckman Instrument APS).21
Fibrinogen determination was rapidly performed accord-
ing to the coagulative method of Clauss.22
2.3. Echocolordoppler examination of carotid arteries
B-mode real-time ultrasound (Toshiba 270 SS) was performed
to evaluate the arterial wall thickness in the carotid arteries
using a probe of 7.5e10.0 MHz. As already reported23,24
patients were examined in the supine position and each
carotid wall or segment was examined to identify the thickest
intimal-medial site. Each scan of the common carotid artery
began just above the clavicle, and the transducer was moved
until the carotid bifurcation and along the internal carotid
artery. Three segments were identified and measured in
antero and posterior planes on each side: the distal 1.0 cm of
the common carotid proximal to the bifurcation, the bifurca-
tion itself, and the proximal 1.0 cm of the internal carotid
artery. At each of these sites we detected any possible plaque
and determined the IMT as defined as the distance between
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the echogenic line representing the intima blood interface and
the outer echogenic line representing the adventitia junction.
Subjects with subclinical carotid atherosclerosis were
considered, in accordance to the joint ESH/ESC guidelines, in
relation to the ultrasound report, both subject with intima-
media thickening (with IMT >0.9 mm and <1.5 mm) and
subjects with asymptomatic carotid plaque (APC) (IMT
>1.5 mm).25
Table 1 e Main characteristics between “CIN-group” and “no-CIN group”. Results of univariate analysis.
No-CIN (n ¼ 486) CIN (n ¼ 105) p value <0.05
Demographic characteristics
Mean age 65.32 $ 12.02 68.94 $ 11.31 0.004
Male n (%) 69.3% (337) 69 (65.7) 0.54
Clinical characteristics n (%)
Diabetes mellitus 150 (30.9%) 44 (42%) 0.03
Smoke 141 (29.0%) 30 (28.6%) 0.97
Ex smoke 132 (27.2%) 22 (20.9%) 0.23
Dyslipidemia 233 (47.9%) 53 (50.5%) 0.72
Family history 189 (38.9%) 45 (42.8%) 0.51
Arterial hypertension 340 (69.9%) 83 (80.0%) 0.05
Anemia 50 (10.3%) 19 (18.1%) 0.03
Previous CRI 61 (12.5%) 28 (26.6%) <0.001
Obesity (BMI >30 kg/m2) 72 (14.8%) 23 (21.9%) 0.09
Previous CABG 39 (8.0%) 14 (13.3%) 0.12
Previous IMA 138 (28.4%) 33 (31.4%) 0.61
Previous AF 42 (8.6%) 9 (8.6%) 0.86
Previous PCI 130 (26.7%) 23 (21.9%) 0.36
Previous HF 24 (4.9%) 7 (6.7%) 0.63
Valvular disease 36 (7.4%) 3 (2.8%) 0.13
Thyroid disease 32 (6.6%) 4 (3.8%) 0.39
Diabetic complication 18 (3.7%) 2 (1.9%) 0.53
Thromboembolic disease 1.0% (5) 2 (1.9%) 0.79
Biological characteristics
Total cholesterol (mg/dl) 171.52 $ 44.12 168.7 $ 41.56 0.56
HDL cholesterol (mg/dl) 43.26 $ 11.89 41.68 $ 12.86 0.22
LDL cholesterol (mg/dl) 100 $ 38.09 104.29 $ 37.73 0.29
Triglycerides (mg/dl) 134.24 $ 73.03 135.79 $ 79.50 0.85
Inflammatory markers
Hs-CRP (mg/L) 1.63 $ 5.5 2.84 $ 4.27 0.03
ESR (mm/h) 17.36 $ 16.67 28.94 $ 21.14 <0.001
Fibrinogen (mg/dl) 368.42 $ 98.15 394.91 $ 113.99 0.02
Diagnosis extracoronary ATS n (%) 215 (44.2%) 68 (64.8%) <0.001
Clinical ATS n (%) 148 (30.4%) 44 (41.9%) 0.03
Preclinica ATS n (%) 67 (13.8%) 24 (22.9%) 0.02
Medications n (%)
Diuretics 106 (21.8%) 37 (35.2%) 0.005
Ace-inhibitors 253 (52.1%) 61 (58.1%) 0.31
Sartans 114 (23.4%) 24 (22.8%) 0.99
Statins 366 (75.3%) 85 (80.9%) 0.26
NSAIDS 414 (85.2%) 90 (85.7%) 0.98
Angiography characteristics
Emergency procedure n (%) 66 (11.16%) 30 (28.6%) <0.001
Bare metal stent n (%) 263 (54.11%) 58 (55.23) 0.91
N%stents 1.44 $ 0.60 1.45 $ 0.55 0.87
Type of contrast media n (%)
Iodixanol (Visipaque) 320 (65.8%) 71 (67.6%) 0.81
Iomeprol (Iomeron) 94 (19.3%) 20 (19.0%) 0.94
Ioversol (Optiray) 72 (14.8%) 14 (13.3%) 0.81
Mean doses of contrast media (cc) 115.1 $ 83.56 136.9 $ 101.73 0.02
Multivessel disease n (%) 200 (41.15%) 45 (42.85) 0.83
0 sick vessels n (%) 115 (23.6%) 18 (17.1%) 0.18
1 sick vessel n (%) 151 (31.0%) 35 (33.3%) 0.73
2 sick vessels n (%) 108 (22.2%) 20 (19%) 0.55
3 sick vessels n (%) 100 (20.6%) 27 (25.7%) 0.29
Common trunk n (%) 28 (5.8%) 10 (1.7%) 0.13
CRI, chronic renal insufficiency; CABG, coronary artery by pass graft; IMA, acute myocardial infarction; AF, atrial fibrillation; PCI, percutaneous
coronary intervention; HF, heart failure; HDL, high density lipoprotein; LDL, low density lipoprotein; hs-CRP, high sensitivity C reactive protein;
ESR: erythrocyte sedimentation rate; ATS, atherosclerosis; ACE, angiotensin converting enzyme; NSAIDs non steroidal anti-inflammatory drugs.
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2.4. Ankle-brachial index measurement
Measurement of Ankle-Brachial Index (ABI) is an easy-to-
perform, inexpensive, reproducible and non-invasive test.19
It was performed with the patient supine; systolic blood
pressure was recorded at both arms and both ankles with an
Esaote Caris Plus ultrasound scanner using a 7.5e10.0 MHz
linear probe.
ABI was calculated for each leg by diving the highest ankle
pressure by highest pressure of both arms. An ABI <0.90 is
widely accepted as a reasonable cut point to confirm the
diagnosis of preclinical atherosclerosis of arteries supplying
the legs.26
2.5. Statistical analysis
Continuous variables were presented as mean $ SD and
compared using Student’s t test. In case of non normal
distribution, non parametric methods were used (Man-
neWhitney U test). Categorical variables were presented as
counts and percentages and compared with c2-test when
appropriate (expected frequency >5). Otherwise, Fisher’s
exact test was used. p value <0.05 was considered statistically
significant. To identify independent characteristics associated
with CIN multivariable logistic regression analysis was used.
Results of this model were presented as Odds Ratio (OR) and
95% confidence intervals (95% CI) for OR. Models were devel-
oped with stepwise techniques and by consideration of
potential confounding factors and of variables that are shown
to be statistically significant at univariate analysis. All data
was processed using MedCalc software version 11.3.0.0.
3. Results
The study population consisted of 591 patients with a mean
age 65.96 $ 11.31 years, 406 (68.69%) were men.
The patient sample was divided up into 2 groups: “CIN-
group” and “no-CIN group”.
The “no-CIN group” included a total of 486 patients, 337
males (69.3%) and 149 females (30.7%) with average age
65.32 $ 12.02 years [Table 1].
The CIN group included a total of 105, 69 males (65.7%) and
36 females (34.3%) with average age 68.94 $ 11.31 years [Table
1].
The main clinical characteristics of the patient population
are summarized in Table 1.
After univariate analysis, by analyzing different features,
the CIN and no-CIN groups resulted to be fully homogeneous
for the characteristics reported in Table 1 ( p > 0.05).
On the contrary, as reported in Table 1, it emerged that
patients of CIN group were older individuals than controls
(68.94 $ 11.31 versus 65.32 $ 12.02 years, respectively;
p ¼ 0.004) and had significantly higher proportion of diabetes
( p ¼ 0.03), renal insufficiency ( p < 0.001), emergency proce-
dure ( p < 0.001), therapy with diuretics ( p ¼ 0.005), anemia
( p ¼ 0.03) compared with patients of “no-CIN group”, while
arterial blood pressure was limit of significance ( p ¼ 0.05).
As regards cardiology procedures, in subjects who devel-
oped CIN a higher dose of contrast media was administered
( p ¼ 0.02), while the compared analysis of the patient groups
in relation to the molecule type chosen to make coronaries
opaque (iodixanol, iomeprol, ioversol), did not show any
significant statistical difference.
An interesting relationship was found between systemic
inflammation and extent of coronary atherosclerosis: an
increase in blood levels of hs-CRP and fibrinogen, corre-
sponded to a proportional increase in the number of diseased
vessels [Figs. 1 and 2], this result could suggest a possible
direct connection between this latest data and risk CIN, but
this correlation is not statistically confirmed in univariate
analysis (multivessel disease p ¼ 0.83; 2 sick vessels p ¼ 0.55; 3
sick vessels p ¼ 0.29) [Table 1].
Moreover a statistically significant difference was found
between the two groups for preprocedural CRP levels
( p ¼ 0.03), serum fibrinogen levels ( p ¼ 0.015) and erythrocyte
sedimentation rate (ESR) ( p < 0.001), particularly an increase
of blood levels of hs-CRP corresponded to a proportional
increase of CIN [Fig. 3].
Another important finding is that the Atherosclerosis
Extracoronary both clinical ( p¼ 0.03) and preclinical ( p¼ 0.02)
was more represented in the CIN group.
After we made a multivariate analysis to identify inde-
pendent factor associated with contrast induced nephrop-
athy, considering the variables that univariate analysis
showed statistically significant difference (diabetes, diuretics,
mean doses of contrast media, anemia, emergency procedure,
inflammatory markers, extracoronary atherosclerosis,
chronic renal insufficiency) and the potential confounding
factors such as multivessel disease, sex, hypertension, type of
contrast media, number of stent. From the logistic regression
analysis age (OR ¼ 1.03; 95%CI 1.01 to 1.05; p ¼ 0.01), diabetes
mellitus (OR ¼ 3.04; 95%CI 1.81 to 5.10; p¼ <0.0001), treatment
with diuretic (OR ¼ 1.04; 95%CI 1.02 to 1.07; p ¼ 0.002), dose of
contrast (OR ¼ 1.84; 95%CI 1.14 to 2.99; p ¼ 0.01); CRP serum
levels (OR ¼ 1.92; 95%CI 1.10 to 3.36; p ¼ 0.02), extracoronary
atherosclerosis both clinical (OR ¼ 1.84; 95%CI 1,16 to 2.94;
p ¼ 0.010) preclinical atherosclerosis (OR ¼ 4.10; 95%CI 2.19 to
7.70; p ¼ <0.0001) and previous chronic renal insufficiency
(CRI) (OR ¼ 2.77; 95%CI 1.67 to 4.60; p ¼ 0.0001), were inde-
pendent predictors of the CIN [Table 2].
Fig. 1 e Linear relationship between fibrinogen serum
levels and number of sick vessels.
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4. Discussion
Contrast induced nephropathy (CIN) is a feared complication
of radiological procedures that expose patients to contrast
media. Although the risk of renal function impairment asso-
ciated with radiologic procedures is low in the general pop-
ulation, it may be very high in selected patient subsets,
especially in cardiac procedures6,15,27 such as percutaneous
coronary intervention (PCI) and coronary angiography. Not
only is this a leading cause of morbidity and mortality, but it
also adds to increased costs in high risk patients undergoing
percutaneous coronary intervention.
In our clinical experience we evaluated a patient pop-
ulation, dividing it into two arms according to the onset of
contrast induced nephropathy after coronarography and/or
percutaneous angioplasty.
By statistical analysis of baseline characteristics of study
population, some peculiar factors seemed to be strongly
correlated to the risk of developing CIN.
The incidence of CIN is considerably higher in elderly
patients, in patients affected by diabetes mellitus, kidney
failure, undergoing diuretic therapy, treated with higher
contrast doses than the general population, according to
literature data5,7,15,28 and in patients with a state of systemic
inflammation and extra cardiac atherosclerosis both clinical
and preclinical. The elderly remain at a higher risk of CIN after
PCI, a few studies have found age older than 70 years to be an
independent predictor of CIN in multivariate analysis.29
Mehran et al, similarly, found eight variables for patients
who underwent PCI (hypotension, intra-aortic balloon pump,
congestive heart failure, chronic kidney disease, diabetes, age
75 years, anemia, and volume of contrast) and assigned
a weighted integer to each variable to make up a score
cumulatively so as to divide low risk (5) and high risk (16)
scores.7 Many studies have found DiabetesMellitus (DM) as an
independent risk factor for CIN.5,15,30 Toprak et al showed that
in patients with preexisting renal insufficiency, Diabetes
Mellitus independently increased the risk of development of
CIN and need for dialysis as opposed to pre-DM and Normal
Fasting states,31 while Berns showed that the incidence of CIN
in diabetics was higher if Cr 4.0 compared to Cr between 2.0
and 4.0 mg/dL. Clearly, there is a synergistic effect of diabetes
and pre existing renal insufficiency.32
As expected, the presence of a previous renal insufficiency,
defined as an estimated glomerular filtration rate (eGFR) of
<60 mL/min/1.73 m2, turned out a very sensitive index of
CIN.6,33 Based on the available evidence in the literature the
risk of CIN is inversely related to the calculated estimated GFR
(eGFR).15
Studies have shown that diuretics and mannitol have no
beneficial effects and may be harmful34,35 and their use
cannot be recommended for CIN prophylaxis. In fact the use
of loop diuretics may actually exacerbate post-procedural
renal function.36 On the other hand preprocedure hydration
seems to be the best strategy for preventing CIN.13e37
Our data showed that the CIN risk increases proportionally
to the doses of contrast media. Intuitively, the less contrast
media administered, the lower the risk for CIN, in fact volume
of contrast remains the primarymodifiable risk factor.38 Many
studies have documented a clear correlation between volume
Table 2 e Independent correlates of CIN.
OR
95% CI
p valueLower Upper
Age 1.03 1.01 1.05 0.01
Diabetes mellitus 3.04 1.81 5.10 <0.0001
Diuretics 1.04 1.02 1.07 0.002
Mean doses of
contrast media (cc)
1.84 1.14 2.99 0.01
Hs-CRP (mg/L) 1.93 1.10 3.36 0.02
Diagnosis extracoronary ATS
Clinical ATS 1.85 1.16 2.94 0.01
Preclinical ATS 4.11 2.19 7.70 <0.0001
Previous CRI 2.77 1.67 4.60 0.0001
Hs-CRP, high sensitivity C reactive protein; ESR: erythrocyte sedi-
mentation rate; ATS, atherosclerosis; CRI, chronic renal
insufficiency.
Fig. 2 e Linear relationship between hs-CRP serum levels
and number of sick vessels.
Fig. 3 e Linear relationship between hs-CRP serum levels
and CIN (contrast induced nephropathy).
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of contrast and risk of CIN.38,39 However, whether incidence of
CIN is dose related or not has also been studied. In their study,
Mekan et al found that the contrast-induced reduction in
renal function was not significantly higher with a higher
volume of contrast (100 mL).40 On the other hand, Kane et al
demonstrated a significant rise in incidence of CIN with
increase of volume of contrast.38 Although the pathogenesis
of this condition is not fully understood, it is most likely the
result of the prolonged vasoconstriction, for alterations in
nitric oxide metabolism that lead to renal vasoconstriction,
and impaired autoregulation induced by contrast media pre-
disposing to medullary hypoxia, in combination with direct
cytotoxicity to the renal tubular epithelium. This may be
further influenced by contributions from several systemic
factors, in fact the damage may be mediated by formation of
free radicals in the acidic tubular environment.41 Therefore,
an appreciation of the factors affecting renal microcirculatory
hemodynamics is pivotal to understanding the pathogenesis
of CIN and the expected response to preventive measures.
In particular, the hemodynamic theory of CIN pathophys-
iology would be indirectly confirmed by another datum we
found, that is, the higher predisposition to CIN occurrence in
subjects undergoing emergency CVG or PCI. In fact contrast-
induced nephropathy frequently complicates primary PCI,
even in patients with normal renal function.42 Actually, the
acute cardiocirculatory failure of these patients could cause
a contrast-induced damage both by worsening kidney hypo-
perfusion and by preventing to take appropriate preventive
measures before intervention. The type of molecule used as
contrast media was not a differential factor between the two
groups: this is easy understandable considering that in our
hemodynamic laboratory only low-osmolar non ionic mono-
mers or iso-osmolar ionic and non-ionic dimers are used, in
accordance with the latest evidences on the least dangerous
molecules for the kidney.43,44
Another very interesting aspect that came up from our
study concerns the role of systemic inflammation.
Although atmultivariate analysis, the fibrinogen levels and
erythrocyte sedimentation rate (ESR) were not independent
predictors, elevated pre-procedural C-reactive protein provide
a strong and independent predictor of CIN.
Recent studies have reached similar results, despite few
studies have investigated hs-CRP as a risk factor for contrast-
induced nephropathy. Gao et al in their study demonstrated
that elevated preprocedural CRP was associated with an
increased risk for CIN in patients undergoing PCI.16 Lyu et al
showed that CRP was a significant and independent predictor
of CIN after primary PCI in patients with STEMI.17 Some
studies indicated that the administration of statins was
associated with reduced incidence of CIN in patients under-
going PCI and the beneficial effect of statins on systematic
inflammation and endothelium dysfunction has been well
documented.45,46
Furthermore, when the degree of systemic inflammation
increased, the number of sick vessels increased too, con-
firming a trend of recent evidences linking hs-CRP to
atherosclerotic disease.47,48 On the basis of these results, we
wondered if there was also a direct relationship between the
number of sick vessels and the CIN risk, but this datum was
not statistically proved. Moreover, despite the fact that no
firm conclusions can be drawn at this stage, it was emerged
from our study as extracoronary atherosclerosis both
preclinical and clinical, may be another strongly predictive
index of CIN after PCI and this could confirm the hypothesis,
made by some authors,49 that atherosclerosis is the actual
link between cardiovascular and renal diseases, even
considering the worse cardiovascular outcome of patients
who develop CIN.10,50 In fact, the systemic inflammatory
process, of which atherosclerosis is an expression, may
induce alterations in the renal microcirculation, predispos-
ing to CIN. Especially to emphasize its role as independent
factor of preclinical atherosclerosis valued at carotid and
lower limbs, in fact, although the total number of patients
with atherosclerosis preclinical in the two groups is very
small, the role of preclinical atherosclerosis, as predictor of
CIN, should not be underestimated: the preclinical athero-
sclerosis, if left to its free evolution, in fact, in addition to the
known cardiac complications, may lead to an increased
susceptibility to CIN. It follows that IMT and ABI if properly
interpreted, becomes an early indicator of damage.
An interesting fact was that after a multivariate analysis,
anemia was not a risk factor, contrary to previous studies,7e9
probably because of the small percentage of subjects with
anemia in the population.
Our study has some limitations: the study included a small
population, admitted to a single center, due to limited avail-
ability of data fields, we could not consider periprocedural
hydration volume, proteinuria, urine output, intra-aortic
balloon pump in our multivariate analysis. In our institution,
prophylactic use of sodium bicarbonate or N-acetylcisteine
infusion is extremely rare due to their conflicting clinical
results, so it was available for our analyses. In addition the
impossibility to conclude causality or exclude unmeasured
confounding as a contributor to the observed association, we
cannot exclude the presence of a selection bias and the
possibility that other factors, might have contributed, at least
in part, to renal impairment, and influenced the clinical
outcome of our patients.
5. Conclusions
The findings of this study on one hand, according to literature
data, provides further epidemiological evidence that, diabetes
mellitus, volume of contrast media, diuretics, kidney failure
are associated with a higher risk of contrast-induced
nephropathy, on the other suggest that patient with high
levels of CRP and extra cardiac atherosclerosis may be more
exposed to CIN. It follows that IMT, ABI and above all, pre-
procedural CRP level if properly interpreted, becomes an early
indicator of CIN.
Pending further studies to confirm these results, in light of
these data, it would be important to be able to better define the
role of both preprocedural CRP level and atherosclerosis with
respect CIN and to assess if preprocedural risk stratification
with these factors as an adjunct to established clinical risk
factors, further confirmed in our study, may be useful as form
of prevention for early identification of high risk patients for
CIN. Research now in progress will almost certainly help
clarify the picture.
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